PURINE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF VIRAL INFECTIONS
    1.
    发明申请
    PURINE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF VIRAL INFECTIONS 审中-公开
    用于治疗病毒感染的嘌呤一磷酸酯制剂

    公开(公告)号:US20140212382A1

    公开(公告)日:2014-07-31

    申请号:US14117815

    申请日:2012-05-16

    摘要: The present invention is directed to compounds, compositions and methods for treating or preventing viral infections using nucleoside analog monophosphate prodrugs. More specifically, HCV, Norovirus, Saporovirus, Dengue virus, Chikungunya virus and Yellow fever in human patients or other animal hosts. The compounds are certain 2,6-diamino 2-C-methyl purine nucleoside monophosphate prodrugs and modified prodrug analogs, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HCV, Norovirus, Saporovirus, Dengue virus, Chikungunya virus and Yellow fever. This invention teaches how to modify the metabolic pathway of 2,6-diamino 2′-C-methyl purine and deliver nucleotide triphosphate(s) to polymerases at heretofore unobtainable therapeutically-relevant concentrations.

    摘要翻译: 本发明涉及使用核苷类似物单磷酸酯前药治疗或预防病毒感染的化合物,组合物和方法。 更具体地,在人类患者或其他动物宿主中,HCV,诺如病毒,Saporovirus,登革热病毒,基孔肯雅病毒和黄热病。 这些化合物是某些2,6-二氨基2-C-甲基嘌呤核苷单磷酸前体药物和修饰的前药类似物及其药学上可接受的盐,前药和其它衍生物。 特别地,这些化合物显示针对HCV,诺如病毒,Saporovirus,登革热病毒,基孔肯雅病毒和黄热病的有效的抗病毒活性。 本发明教导了如何修饰2,6-二氨基2'-C-甲基嘌呤的代谢途径,并将迄今为止无法获得的治疗相关浓度的核苷酸三磷酸转移至聚合酶。